OBJECTIVES: We tested the efficacy and safety of linopirdine, a novel phenylindolinone, in the treatment of Alzheimer's disease. METHODS: A multicentre, randomized, double-blind, parallel group, placebo-controlled trial of linopirdine (30 mg three times per day or placebo). Patients (n = 382, 55% male, 98% Caucasian, age range 51-95 years) with mild or moderate Alzheimer's disease, of whom 375 received at least one treatment dose were analysed. There were no important differences between the groups at baseline. RESULTS: No difference was seen in Clinical Global Impression scores between patients receiving placebo and those receiving linopirdine (n = 189). Small differences in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores were seen throughout the study favouring linopirdine; at 6 months the ADAS-Cog scores were 20.2 (linopirdine) and 22.1 (placebo) p = 0.01. CONCLUSIONS: This trial did not detect clinically meaningful differences in patients receiving linopirdine for 6 months, despite evidence of a small degree of improved cognitive function. Further studies may benefit from more sensitive tests of treatment effects in Alzheimer's disease.
RCT Entities:
OBJECTIVES: We tested the efficacy and safety of linopirdine, a novel phenylindolinone, in the treatment of Alzheimer's disease. METHODS: A multicentre, randomized, double-blind, parallel group, placebo-controlled trial of linopirdine (30 mg three times per day or placebo). Patients (n = 382, 55% male, 98% Caucasian, age range 51-95 years) with mild or moderate Alzheimer's disease, of whom 375 received at least one treatment dose were analysed. There were no important differences between the groups at baseline. RESULTS: No difference was seen in Clinical Global Impression scores between patients receiving placebo and those receiving linopirdine (n = 189). Small differences in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores were seen throughout the study favouring linopirdine; at 6 months the ADAS-Cog scores were 20.2 (linopirdine) and 22.1 (placebo) p = 0.01. CONCLUSIONS: This trial did not detect clinically meaningful differences in patients receiving linopirdine for 6 months, despite evidence of a small degree of improved cognitive function. Further studies may benefit from more sensitive tests of treatment effects in Alzheimer's disease.
Authors: Sean P Nassoiy; Favin S Babu; Heather M LaPorte; Kenneth L Byron; Matthias Majetschak Journal: Clin Exp Pharmacol Physiol Date: 2018-04-27 Impact factor: 2.557
Authors: Jennifer van der Horst; Rian W Manville; Katie Hayes; Morten B Thomsen; Geoffrey W Abbott; Thomas A Jepps Journal: Arterioscler Thromb Vasc Biol Date: 2020-03-19 Impact factor: 8.311
Authors: Jacob D Porter; Oscar Vivas; C David Weaver; Abdulmohsen Alsafran; Elliot DiMilo; Leggy A Arnold; Eamonn J Dickson; Chris Dockendorff Journal: Bioorg Med Chem Lett Date: 2019-09-14 Impact factor: 2.823
Authors: Mauricio O Nava-Mesa; Lydia Jiménez-Díaz; Javier Yajeya; Juan D Navarro-Lopez Journal: Front Cell Neurosci Date: 2014-06-25 Impact factor: 5.505